Transcranial magnetic stimulation is a non-surgical procedure used to treat brain disorders: a scalp coil sends magnetic pulses that change activity in brain circuits. Support is strongest for depression unresponsive to medication, and solid for obsessive-compulsive and Parkinson's movement symptoms. For healthy adults hoping to slow brain aging, no direct human evidence exists. Side effects are mostly short-lived headache and scalp discomfort; metal implants near the head rule it out. (Full Review)

Protocol

Standard 10 Hz rTMS (depression)

3,000 pulses, 5 sessions weekly for 4–6 weeks

Left dorsolateral prefrontal cortex at 120% of motor threshold; about 37.5 minutes per session

Intermittent theta-burst (depression)

About 3 minutes per session, 5 days weekly for 4–6 weeks

Left dorsolateral prefrontal cortex; not meaningfully worse than 10 Hz

Accelerated SNT (depression)

10 daily sessions for 5 days

1,800-pulse intermittent theta-burst sessions 50 minutes apart at 90% of depth-adjusted motor threshold; brain-activity-scan targeting

Time to effect

Depression (daily sessions)

Weeks 4–6

Benefit separated from sham stimulation

Depression (accelerated SNT)

Within 5 days

Remission in an unblinded study from the developing lab

Smoking craving

Within 2 weeks

Craving fell with deep TMS

Benefits

High: Relief of depressive symptoms; reduction of obsessive-compulsive symptoms; improved Parkinson's disease motor symptoms

Medium: Reduced smoking, alcohol and stimulant use; acute relief of migraine with aura; improved cognition in cognitive impairment and after stroke; post-stroke motor, language and swallowing recovery; reduced visuospatial neglect after stroke; recovery of consciousness after severe brain injury; fewer negative symptoms of schizophrenia; improved sleep quality in insomnia; reduced ADHD symptoms; reduced core autism symptoms; tinnitus relief; improved coordination in cerebellar ataxia; reduced limb spasticity in multiple sclerosis; reduced anxiety symptoms

Low: Chronic pain relief; reduced auditory hallucinations in schizophrenia; reduced post-traumatic stress symptoms; fewer seizures in drug-resistant epilepsy; migraine prevention; cognitive performance in healthy adults

Speculative: Slowing brain aging in healthy adults

Contraindications

Absolute contraindication: Conductive, ferromagnetic or other magnetic-sensitive metal implanted in the head or within 30 cm of the coil (such as cochlear implants, aneurysm clips or coils)

Absolute contraindication: Active or inactive implanted stimulators (including deep brain stimulators and vagus nerve stimulators)

Cardiac pacemakers or implantable cardioverter defibrillators (labeling precaution)

Epilepsy or brain lesions; any seizure history other than electroconvulsive therapy-induced or isolated infant fever seizures (careful risk-benefit weighing)

Current psychotic symptoms, raised intracranial pressure, brain tumors or repeated or severe head trauma (careful risk-benefit weighing)

Bipolar disorder without mood-stabilizing treatment (inferred, not tested)

Key Interactions

Seizure-threshold-lowering drugs (tricyclic antidepressants such as amitriptyline; antipsychotics such as clozapine): close seizure monitoring

Antidepressants started with the course (sertraline, escitalopram): additive effect

Benzodiazepines (lorazepam, clonazepam): linked with lower response

Psychostimulants (such as methylphenidate and amphetamine salts): linked with higher response

D-cycloserine: raised response; specialist or research use only

Memantine: may blunt benefit that depends on brain rewiring

Varenicline: additive quit effect

Sleep deprivation: featured among seizure risk factors

Theoretical (inferred from mechanism)

Over-the-counter sedating antihistamines (diphenhydramine, doxylamine) at high doses: additive lowering of seizure threshold

High-dose caffeine (caffeine tablets, pre-workout products): additive increase in brain excitability and seizure susceptibility

Heavy alcohol use or abrupt alcohol or sedative withdrawal: lowered seizure threshold

GABA-enhancing supplements (kava, valerian): blunted response

Supplements with putative antidepressant action (omega-3 fatty acids, saffron): additive mood effects

Risk & Side Effects

High: Headache; scalp pain and discomfort at the stimulation site

Low: Seizure; treatment-emergent mania or hypomania; worsening depression or suicidality; transient hearing changes from coil noise; dizziness or lightheadedness

Speculative: Unknown long-term effects of repeated courses

Monitoring

Marker	Target	Why
PHQ-9	More than 50% fall from baseline	Tracks benefit
HAM-D	10 or below	Confirms remission
Resting motor threshold	No established target; track change from own baseline	Sets stimulation intensity
Serum sodium	135–145 mmol/L	Abnormal electrolytes can lower seizure threshold
YMRS	8 or below	Rising score signals emerging mania
Suicidal ideation (PHQ-9 item 9 or a structured suicide-risk scale)	No established target; any new or worsening ideation prompts clinician review	Labeled warning for worsening depression or suicidality
MoCA	26 or above	Tracks change when TMS targets memory decline
Pure-tone audiometry	No established target; compare with own baseline	Detects noise-related hearing change

Cadence: Baseline before the first session; self-rated scores at sessions 5, 10, 20 and 30 (or daily during accelerated courses); clinician-rated scores at baseline, week 3 and course end; motor threshold weekly and after medication changes; mania rating weekly in bipolar disorder; scores repeated at 3, 6, 9 and 12 months after the course

Qualitative Assessment

Mood, interest and pleasure in daily activities
Sleep quality and morning restfulness
Energy and motivation
Cognitive clarity, word-finding and everyday memory
Headache and scalp-discomfort diary after sessions
Cravings and cigarettes per day when used for smoking cessation
Daily function at work and home

Transcranial Magnetic Stimulation for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment